| Literature DB >> 24369750 |
Krishna Khairnar1, Mahendra P Raut, Rajshree H Chandekar, Swapnil G Sanmukh, Waman N Paunikar.
Abstract
BACKGROUND: The bacteriophage therapy is an effective antimicrobial approach with potentially important applications in medicine and biotechnology which can be seen as an additional string in the bow. Emerging drug resistant bacteria in aquaculture industry due to unrestricted use of antibiotics warrants more sustainable and environmental friendly strategies for controlling fish infections.The isolated bacteria from fish lesions was characterised based on isolation on selective and differential medium like Pseudomonas agar, gram staining, biochemical tests and 16SrRNA sequencing. The metallo-beta-lactamase (MBL) producing bacterial isolate was evaluated using Imipenem - Ethylenediaminetetraacetic acid (EDTA) disk method. The specific bacteriophage was isolated and concentrated using coal bed developed in our lab at CSIR-NEERI. The isolated and enriched bacteriophage was characterised by nucleotide sequencing and electron microscopy. The phage therapy was applied for treating ulcerative lesion in fish.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24369750 PMCID: PMC3913374 DOI: 10.1186/1746-6148-9-264
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Figure 1Isolation of by cotton swab from wound of infected
Figure 2Isolated on Pseudomonas agar from the wound of infected .
Figure 3Isolation of bacteriophages against .
Figure 4Figure showing Imipenem EDTA disk to test metallo β lactamase (MBL) production, disc 1: Imipenen; disc 2: Imipenem with EDTA; disc 3: EDTA. A) MBL Negative Pseudomonas aerouginosa ATCC 27853 as control and B) MBL positive Pseudomonas aerouginosa isolate.
Figure 5Transmission electron microscopy images of (A) Pseudomonas phage head; (B, C and D) Bacteriophage mediated lysis of at different point of time.
Figure 6A plot of phage therapy. (A) effect on infected Clarias gariepinus. (B) Interaction between the treatment types.
Analysis of variance (ANOVA) based on treatment type and treatment phases of phage therapy effect on infected
| Treatment (Control/treated) | 1 | 416.02 | 416.025 | 71.63 | <0.001 |
| Phase (Initial/final) | 1 | 378.23 | 378.225 | 65.12 | <0.001 |
| Interaction | 1 | 225.63 | 225.625 | 38.85 | <0.001 |
| Error | 36 | 209.10 | 5.808 | | |
| Total | 39 | 1228.97 |
Figure 7Representative image of (A) infected without phage treatment; (B) infected subjected to phage treatment.